Furthermore, this impairment is correlated with reduced functional connectivity in the brain
Liu Z-Z, Duan X-X, Yuan M-C, Yu J, Hu X, Han X, et al
March 8, 2026: More Deaths, Adverse Events Reported About Patients Taking Mounjaro, Other GLP-1s The U.K.s Medicines and Healthcare products Regulatory Authority received 1,296 reports of pancreatitis involving patients taking GLP-1 drugs (like Mounjaro) between 2007 and 2025
Soluble Fibre: The Gut Microbiomes GLP-1 Ally Soluble fibresespecially prebiotic fibres like inulin, pectin, beta-glucan and partially hydrolysed guar gum (PHGG)ferment in the colon and feed beneficial gut bacteria
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function